docetaxel anhydrous and Hematologic Neoplasms
docetaxel anhydrous has been researched along with Hematologic Neoplasms in 3 studies
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Arslan, C; Uslu, R | 1 |
Becker, PS; Cassaday, RD; De Padova, N; Lindstrom, S; Puri, A; Ulrickson, ML | 1 |
Chow, LW; Yip, AY | 1 |
Other Studies
3 other study(ies) available for docetaxel anhydrous and Hematologic Neoplasms
Article | Year |
---|---|
Secondary haematological malignancies in the BCIRG 001 study.
Topics: Cyclophosphamide; Docetaxel; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Taxoids | 2013 |
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids | 2017 |
Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles.
Topics: Adult; Aged; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; China; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunohistochemistry; Incidence; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2006 |